๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

โœ Scribed by Robert S DiPaola; Yu-Hui Chen; Mark Stein; David Vaughn; Linda Patrick-Miller; Michael Carducci; Bruce Roth; Eileen White; George Wilding


Book ID
119905606
Publisher
BioMed Central
Year
2010
Tongue
English
Weight
939 KB
Volume
8
Category
Article
ISSN
1479-5876

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Interferon-ฮฑ-2a with or without 13-cis r
โœ Sophie D. Fossรฅ; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin